Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | APAF1 | O14727 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.48 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MDH2 | P40926 | 2/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8255367 | 0.91 | CASP3 (0.52) | CASP3MEN1KMT2AGAAAPAF1 | |
| SCHEMBL21310500 | 0.85 | CHRM5 (0.44) | CASP3MEN1KMT2AGAAAPAF1 | |
| SCHEMBL14938439 | 0.78 | MEN1 (0.71) | CASP3MEN1KMT2AGAAAPAF1 | |
| SCHEMBL3097335 | 0.78 | MEN1 (0.56) | CASP3MEN1KMT2AGAAAPAF1 | |
| SCHEMBL3088630 | 0.77 | MEN1 (0.54) | CASP3MEN1KMT2AGAAAPAF1 | |
| SCHEMBL21310656 | 0.76 | TP53 (0.45) | CASP3MEN1KMT2AGAAAPAF1 | |
| SCHEMBL1858845 | 0.76 | CMA1 (0.47) | CASP3MEN1KMT2AGAAAPAF1 | |
| SCHEMBL11623661 | 0.75 | HDAC1 (0.62) | CASP3MEN1KMT2AAPAF1HDAC1 | |
| SCHEMBL3851940 | 0.74 | MEN1 (0.77) | CASP3MEN1KMT2AGAAAPAF1 | |
| SCHEMBL29173729 | 0.74 | HDAC1 (0.63) | CASP3MEN1KMT2AGAAAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019163865-A1 | DIBENZAZEPINE DERIVATIVE HAVING NITROGEN-CONTAINING HETEROCYCLIC RING | 大日本住友製薬株式会社 | 2019-08-29 | — | — | WO | disclosed |
| US-20100129473-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-7622461-B2 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090239840-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| EP-2088147-A1 | Dibenzo-condensed azepine, diazepine, oxazepine and thiazepine derivatives as muscarinic agonists and methods of treatment of neuropsychiatric disorders | Arcadia Pharmaceuticals Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| US-7550454-B2 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7517871-B2 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1696931-B1 | AMINO SUBSTITUTED DIARYL[A,D]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARM INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7491715-B2 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20070197502-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | EK FREDRIK | 2007-08-23 | — | — | US | disclosed |
| US-20060252744-A1 | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents | ACADIA PHARMACEUTICALS INC. | 2006-11-09 | — | — | US | disclosed |
| US-20060199798-A1 | Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | EK FREDRIK | 2006-09-07 | — | — | US | disclosed |
| US-20060194784-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | EK FREDRIK | 2006-08-31 | — | — | US | disclosed |
| US-20050192268-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS INC. | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129473-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | CHRM4, CHRM5, CHRM1 | CASP3 3829/4885MEN1 3233/4885KMT2A 416/4885 |
| US-20070197502-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | CHRM4, CHRM5, CHRM1 | CASP3 3859/4885MEN1 3177/4885KMT2A 408/4885 |
| US-20060252744-A1 | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents | DRD3, DRD2, PNMT | CASP3 3118/4885MEN1 4794/4885KMT2A 2217/4885 |
| US-20060194784-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | CHRM4, CHRM5, CHRNA10 | CASP3 4063/4885MEN1 2879/4885KMT2A 839/4885 |
| US-20090239840-A1 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | CHRM4, CHRM5, CHRNA10 | CASP3 4063/4885MEN1 2879/4885KMT2A 839/4885 |
| US-20050192268-A1 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | CHRM4, CHRM5, CHRNA10 | CASP3 4063/4885MEN1 2879/4885KMT2A 839/4885 |
| US-20060199798-A1 | Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | OPRL1, CHRM4, CNR1 | CASP3 4166/4885MEN1 3032/4885KMT2A 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.